Egle Therapeutics

  • Biotech or pharma, therapeutic R&D

Spin out of the Institut Curie backed by a 40M€ Series A plus a research collaboration with Takeda, Egle Therapeutics is a clinical stage biotechnology company focused on developing first-in class immunotherapies targeting immune suppressor regulatory T-cells. The lead asset in oncology EGL-001 is in phase 1/2 clinical trail as a single agent and in combination with Keytruda. EGL-003 the lead asset for the treatment of autoimmune disease will be entering the clinic in 2H2025.

Address

Suresnes
France

Website

https://www.egle-tx.com

Contact Exhibitor


Loading
View all Partnering Companies

white squarewhite

BIO DOUBLE HELIX SPONSORS

Our sponsors help support BIO's mission to support and advocate for the biotechnology industry.

BIO HELIX SPONSORS